Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imeglimin and Cimetidine Interaction Study
NCT03618316Phase 1Completed
- Sponsor
- Poxel SA
- Start
- Jun 2018
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of imeglimin in type 2 diabetes mellitus (T2DM), sponsored by Poxel SA. Primary endpoint: PK parameters of imeglimin at Day 1. Started Jun 2018; status: completed.
02
Drugs
imeglimin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03618316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03618316.